

In the Claims

1-40 (canceled).

41 (new). A monoclonal antibody selected from the monoclonal antibody 16D10, an antigen binding fragment or derivative thereof, or an antibody which essentially binds to the same epitope as monoclonal antibody 16D10.

42 (new). The antibody according to claim 41, wherein said antibody is humanized, chimeric or human.

43 (new). The antibody according to claim 41, wherein the antibody is of the IgG type.

44 (new). The antibody according to claim 41, wherein the antibody is a single chain antibody.

45 (new). A kit for diagnosis of a pancreatic pathology, comprising a monoclonal antibody selected from the monoclonal antibody 16D10, an antigen binding fragment or derivative thereof, or an antibody which essentially binds to the same epitope as monoclonal antibody 16D10, and optionally a means for detecting the immunological complex resulting from the immunological reaction between the biological sample and said antibody.

46 (new). A method of detection *in vitro* of a subject suffering from a pancreatic pathology, comprising contacting a biological sample from the subject with an antibody and detecting the formation of immunological complexes resulting from the immunological reaction between said antibody and said biological sample;
wherein said antibody:

a) can specifically recognize a glycopeptide comprising 1 to 40 repetitions of the peptide sequence described in SEQ ID NO: 14 and glycosylated by one or more enzymes having ose-

transferase activity selected in the group consisting of Core 2 $\beta(1-6)$ N-acetylglucosaminyltransferase (C2GnT), fucosyltransferase FUT3 which has $\alpha(1-3)$ and $\alpha(1-4)$ fucosyltransferase activity, or fucosyltransferase FUT7 which has $\alpha(1-3)$ fucosyltransferase activity; or

b) is a monoclonal antibody selected from monoclonal antibody 16D10, an antigen binding fragment or derivative thereof, and an antibody which essentially binds to the same epitope as monoclonal antibody 16D10.

47 (new). The method according to claim 46, wherein said antibody is the antibody J28, an antigen binding fragment or derivative thereof, or an antibody which essentially binds to the same epitope or determinant as the J28 antibody.

48 (new). The method according to claim 46, wherein said antibody is the antibody 16D10, an antigen binding fragment or derivative thereof, or an antibody which essentially binds to the same epitope or determinant as the 16D10.

49 (new). The method according to claim 46, wherein said biological sample is a sample of pancreatic tissue.

50 (new). The method according to claim 46, wherein said biological sample is a biological fluid selected from pancreatic juices, serum or urine.

51 (new). The method according to claim 46, wherein the method enables the detection of a subject suffering from pancreatic cancer.

52 (new). A composition of matter comprising:

a) pharmaceutical or vaccine composition comprising:

i) a glycopeptide comprising 1 to 40 repetitions of the peptide sequence described in SEQ ID NO: 14 and glycosylated by one or more enzymes having ose-transferase activity selected in the group consisting of Core 2 $\beta(1-6)$ N-

acetylglucosaminyltransferase (C2GnT), fucosyltransferase FUT3 which has $\alpha(1-3)$ and $\alpha(1-4)$ fucosyltransferase activity, or fucosyltransferase FUT7 which has $\alpha(1-3)$ fucosyltransferase activity;

ii) a glycopeptide comprising 1 to 40 repetitions of the peptide sequence described in SEQ ID NO: 14 and glycosylated by the enzymes C2GnT and FUT3;

iii) a glycopeptide comprising 1 to 40 repetitions of the peptide sequence described in SEQ ID NO: 14 and glycosylated by the enzymes C2GnT and FUT7; or

iv) a glycopeptide comprising 1 to 40 repetitions of the peptide sequence described in SEQ ID NO: 14 and glycosylated by the enzymes C2GnT, FUT3 and FUT7; or

b) a pharmaceutical composition comprising an antibody that can specifically recognize a glycopeptide comprising 1 to 40 repetitions of the peptide sequence described in SEQ ID NO: 14 and glycosylated by one or more enzymes having ose-transferase activity selected in the group consisting of Core 2 $\beta(1-6)$ N-acetylglucosaminyltransferase (C2GnT), fucosyltransferase FUT3 which has $\alpha(1-3)$ and $\alpha(1-4)$ fucosyltransferase activity, or fucosyltransferase FUT7 which has $\alpha(1-3)$ fucosyltransferase activity.

53 (new). The composition of matter according to claim 52, wherein said composition of matter comprises a pharmaceutical composition comprising an antibody and:

i) the glycopeptide specifically recognized by said antibody is glycosylated by the enzymes C2GnT and FUT3;

ii) the glycopeptide specifically recognized by said antibody is glycosylated by the enzymes C2GnT and FUT7;

iii) the glycopeptide specifically recognized by said antibody is glycosylated by the enzymes C2GnT, FUT3 and FUT7;

iv) the glycopeptide specifically recognized by said antibody comprises between 1 and 15 of said repetitions;

v) said antibody is the antibody J28, an antigen binding fragment or derivative thereof, or an antibody which essentially binds to the same epitope or determinant as the J28 antibody; or

vi) said antibody is the antibody 16D10, an antigen binding fragment or derivative thereof, or an antibody which essentially binds to the same epitope or determinant as the 16D10 antibody;

54 (new). The composition of matter according to claim 52, wherein said pharmaceutical or vaccine composition comprises a glycopeptide and said glycopeptide is further glycosylated by $\alpha(1-3)$ galactosyltransferase (GT).

55 (new). The composition of matter according to claim 52, wherein said pharmaceutical or vaccine composition comprises a glycopeptide and said glycopeptide comprises between 1 and 15 of said repetitions.

56 (new). The composition of matter according to claim 52, wherein said pharmaceutical or vaccine composition comprises a glycopeptide and said glycopeptide is recombinant.

57 (new). The composition of matter according to claim 52, wherein said pharmaceutical or vaccine composition comprises a glycopeptide and said glycopeptide purified from a biological fluid.

58 (new). The composition of matter according to claim 52, wherein said pharmaceutical or vaccine composition comprises a glycopeptide and said glycopeptide is loaded on antigen-presenting cells.

59 (new). A method for a the treatment of a pancreatic disease in a subject comprising administering an effective dose of a pharmaceutical composition comprising a glycopeptide comprising 1 to 40 repetitions of the peptide sequence described in SEQ ID NO: 14 and glycosylated by one or more enzymes having ose-transferase activity selected in the group consisting of Core 2 $\beta(1-6)$ N-acetylglucosaminyltransferase (C2GnT), fucosyltransferase FUT3 which has $\alpha(1-3)$ and $\alpha(1-4)$ fucosyltransferase activity, or fucosyltransferase FUT7 which has $\alpha(1-3)$ fucosyltransferase activity.

60 (new). The method according to claim 59, wherein the pancreatic disease is pancreatic cancer.

61 (new). A method for the treatment of a pancreatic disease in a subject comprising administering an effective dose of a pharmaceutical composition comprising an antibody that can specifically recognize a glycopeptide comprising 1 to 40 repetitions of the peptide sequence described in SEQ ID NO: 14 and glycosylated by one or more enzymes having ose-transferase activity selected in the group consisting of Core 2 β (1-6) N-acetylglucosaminyltransferase (C2GnT), fucosyltransferase FUT3 which has α (1-3) and α (1-4) fucosyltransferase activity, or fucosyltransferase FUT7 which has α (1-3) fucosyltransferase activity.

62 (new). The method according to claim 61, wherein the pancreatic disease is pancreatic cancer.